T1	PROC 46 105	Estudio a largo plazo para estudiar la seguridad y eficacia
T2	CHEM 145 155	amlodipino
#1	AnnotatorNotes T2	C0051696; amlodipine; Organic Chemical · Pharmacologic Substance
T3	DISO 173 185	hipertensión
#2	AnnotatorNotes T3	C0020538; Hypertensive disease; Disease or Syndrome
T4	PROC 209 237	Estudio de extensión abierto
T5	PROC 270 322	evaluar la seguridad, la tolerabilidad y la eficacia
T6	PROC 327 338	tratamiento
#3	AnnotatorNotes T6	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T7	PROC 353 364	monoterapia
#4	AnnotatorNotes T7	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T8	CHEM 393 403	amlodipino
#5	AnnotatorNotes T8	C0051696; amlodipine; Organic Chemical · Pharmacologic Substance
T9	DISO 421 442	hipertensión esencial
#6	AnnotatorNotes T9	C0085580; Essential Hypertension; Disease or Syndrome
T10	DISO 480 504	tensión arterial elevada
#7	AnnotatorNotes T10	C0020538; Hypertensive disease; Disease or Syndrome
T11	DISO 532 553	Hipertensión esencial
#8	AnnotatorNotes T11	C0085580; Essential Hypertension; Disease or Syndrome
T12	PROC 683 693	evaluación
#9	AnnotatorNotes T12	C1261322; Evaluation procedure; Health Care Activity
T13	PROC 742 751	protocolo
#10	AnnotatorNotes T13	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T14	PROC 586 622	consentimiento informado por escrito
#11	AnnotatorNotes T14	C0811741; Obtain informed written consent; Health Care Activity
T15	DISO 938 960	acontecimiento adverso
#12	AnnotatorNotes T15	C0877248; Adverse event; Pathologic Function
T16	CHEM 986 993	fármaco
#13	AnnotatorNotes T16	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T17	CHEM 109 115	LCZ696
#14	AnnotatorNotes T17	C2933615; LCZ 696; Organic Chemical
T18	CHEM 124 130	LCZ696
#15	AnnotatorNotes T18	C2933615; LCZ 696; Organic Chemical
T19	CHEM 343 349	LCZ696
#16	AnnotatorNotes T19	C2933615; LCZ 696; Organic Chemical
T20	PROC 1199 1208	protocolo
#17	AnnotatorNotes T20	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T21	DISO 1240 1257	hipersensibilidad
#18	AnnotatorNotes T21	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T22	CHEM 1264 1285	diuréticos tiazídicos
#19	AnnotatorNotes T22	C0012802; Thiazide Diuretics; Organic Chemical · Pharmacologic Substance
T23	CHEM 367 373	LCZ696
#20	AnnotatorNotes T23	C2933615; LCZ 696; Organic Chemical
T24	Date 13 17	2013
T25	Date 54 67	a largo plazo
T26	LIVB 159 168	pacientes
#21	AnnotatorNotes T26	C0030705; Patients; Patient or Disabled Group
T27	Date 238 251	a largo plazo
T28	Duration 253 263	52 semanas
T29	LIVB 407 416	pacientes
#22	AnnotatorNotes T29	C0030705; Patients; Patient or Disabled Group
T30	LIVB 466 475	Pacientes
#23	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	LIVB 698 707	Pacientes
#24	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group
T32	LIVB 859 871	investigador
#25	AnnotatorNotes T32	C0035173; Research Personnel; Professional or Occupational Group
T33	LIVB 901 910	Pacientes
#26	AnnotatorNotes T33	C0030705; Patients; Patient or Disabled Group
T34	LIVB 1025 1034	Pacientes
#27	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T37	LIVB 1226 1235	Pacientes
#28	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	PHYS 480 496	tensión arterial
#29	AnnotatorNotes T38	C0005823; Blood Pressure; Organism Function
A1	Status T21 History_of
A2	Status T15 History_of
#30	AnnotatorNotes T5	C0511730; Identify product efficacy and safety issues; Health Care Activity + C3274448; Tolerability Study; Research Activity
#31	AnnotatorNotes T25	C0443252; Long-term; Temporal Concept
#32	AnnotatorNotes T27	C0443252; Long-term; Temporal Concept
#33	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity + C0023981; Longitudinal Studies; Research Activity
T35	Neg_cue 1108 1115	excluir
T36	Observation 1119 1143	participar en el estudio
A3	Assertion T36 Negated
#34	AnnotatorNotes T36	C1278516; Patient participation status; Finding
T39	Observation 1055 1064	condición
#35	AnnotatorNotes T39	C4745084; Medical Condition; Finding
T40	PROC 1076 1083	estudio
#36	AnnotatorNotes T40	C0681814; research study; Research Activity
R1	Overlap Arg1:T1 Arg2:T25	
R2	Combined_with Arg1:T18 Arg2:T2	
R3	Experiences Arg1:T26 Arg2:T3	
R4	Experiences Arg1:T26 Arg2:T18	
R5	Experiences Arg1:T26 Arg2:T17	
R6	Overlap Arg1:T4 Arg2:T27	
R7	Has_Duration_or_Interval Arg1:T4 Arg2:T28	
R8	Used_for Arg1:T19 Arg2:T6	
R9	Used_for Arg1:T19 Arg2:T7	
R10	Combined_with Arg1:T23 Arg2:T8	
R11	Experiences Arg1:T29 Arg2:T6	
R12	Experiences Arg1:T29 Arg2:T23	
R13	Experiences Arg1:T29 Arg2:T9	
R14	Experiences Arg1:T30 Arg2:T10	
R15	Experiences Arg1:T30 Arg2:T38	
R17	Before Arg1:T14 Arg2:T12	
T41	Observation 718 728;739 751	completado el protocolo
T42	Observation 776 812	capaces de continuar de forma segura
R19	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T42	
R20	Before Arg1:T41 Arg2:T42	
R21	Experiences Arg1:T33 Arg2:T15	
R22	Causes Arg1:T16 Arg2:T15	
T43	Quantifier_or_Qualifier 961 966	grave
#37	AnnotatorNotes T43	C1547227; Severe -Severity of Illness Code; Intellectual Product
R23	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T43	
R24	Overlap Arg1:T39 Arg2:T40	
R25	Experiences Arg1:T34 Arg2:T39	
R26	Experiences Arg1:T34 Arg2:T36	
R27	Before Arg1:T39 Arg2:T36	
R28	Negation Arg1:T35 Arg2:T36	
R29	Experiences Arg1:T37 Arg2:T21	
R30	Causes Arg1:T22 Arg2:T21	
#38	AnnotatorNotes T4	C1709323; Open Label Study; Research Activity (?)
#39	AnnotatorNotes T41	C2732579; Completion of clinical trial; Finding
A4	Experiencer T34 Patient
A5	Experiencer T37 Patient
A6	Experiencer T33 Patient
A7	Experiencer T32 Other
A8	Experiencer T31 Patient
A9	Experiencer T26 Patient
A10	Experiencer T29 Patient
A11	Experiencer T30 Patient
